Drug Type Small molecule drug |
Synonyms- |
Mechanism FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists) + [8] |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H19ClN4O4 |
InChIKeyWOSKHXYHFSIKNG-UHFFFAOYSA-N |
CAS Registry417716-92-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Angiomatosis | Phase 2 | - | - | |
Glioblastoma | Phase 2 | - | - | |
Melanoma | Phase 2 | - | - |